A novel crizotinib-resistant solvent-front mutation responsive to cabozantinib therapy in a patient with ROS1-rearranged lung cancer

Clinical Cancer Research

Volumn 22, Issue 10, 2016, Pages 2351-2358

  Drilon, Alexander ^a,b   Somwar, Romel ^a   Wagner, Jacob P ^c   Vellore, Nadeem A ^d   Eide, Christopher A ^e,f   Zabriskie, Matthew S ^d   Arcila, Maria E ^a   Hechtman, Jaclyn F ^a   Wang, Lu ^a   Smith, Roger S ^a   Kris, Mark G ^a,b   Riely, Gregory J ^a,b   Druker, Brian J ^e,f   O'Hare, Thomas ^d   Ladanyi, Marc ^a   Davare, Monika A ^c  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

^c OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^d UNIVERSITY OF UTAH   (United States)

^e OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^f HOWARD HUGHES MEDICAL INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CABOZANTINIB; CD74 ANTIGEN; CISPLATIN; CRIZOTINIB; PEMETREXED; PROTEIN TYROSINE KINASE; REACTIVE OXYGEN METABOLITE; ANILIDE; B LYMPHOCYTE ANTIGEN; HLA ANTIGEN CLASS 2; INVARIANT CHAIN; ONCOPROTEIN; PYRAZOLE DERIVATIVE; PYRIDINE DERIVATIVE; ROS1 PROTEIN, HUMAN;

ADULT; ANTIGEN EXPRESSION; APOPTOSIS; ARTICLE; BINDING SITE; CANCER SURVIVAL; CARCINOMATOSIS; CASE REPORT; CELL VIABILITY ASSAY; CHROMOSOME REARRANGEMENT; COMPUTER ASSISTED TOMOGRAPHY; CRYSTAL STRUCTURE; DRUG BINDING; DRUG CONFORMATION; DRUG EFFICACY; DRUG POTENCY; DRUG RESPONSE; DRUG SELECTIVITY; DRUG SENSITIVITY; ENZYME INHIBITION; EXON; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; FUNCTIONAL ASSESSMENT; GENE; GENE MUTATION; HUMAN; HUMAN CELL; HYDROGEN BOND; IMMUNOBLOTTING; LUNG ADENOCARCINOMA; LUNG CANCER; LUNG NODULE; LYMPH NODE BIOPSY; LYMPHADENOPATHY; MOLECULAR DOCKING; MOLECULAR DYNAMICS; MULTIPLE CYCLE TREATMENT; NEXT GENERATION SEQUENCING; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; ROS1 GENE; SITE DIRECTED MUTAGENESIS; STATIC ELECTRICITY; STRUCTURAL MODEL; ADENOCARCINOMA; DRUG EFFECTS; DRUG RESISTANCE; GENETICS; LUNG TUMOR; MIDDLE AGED; MUTATION; ONCOGENE; PHASE 2 CLINICAL TRIAL (TOPIC); TUMOR CELL LINE;

ADENOCARCINOMA; ANILIDES; ANTIGENS, DIFFERENTIATION, B-LYMPHOCYTE; CELL LINE, TUMOR; CLINICAL TRIALS, PHASE II AS TOPIC; DRUG RESISTANCE, NEOPLASM; FEMALE; HISTOCOMPATIBILITY ANTIGENS CLASS II; HUMANS; LUNG NEOPLASMS; MIDDLE AGED; MUTATION; ONCOGENES; PROTEIN-TYROSINE KINASES; PROTO-ONCOGENE PROTEINS; PYRAZOLES; PYRIDINES;

EID: 84969257134     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-15-2013     Document Type: Article

References (31)

1. Davare MA, Tognon CE. Detecting and targeting oncogenic fusion proteins in the genomic era. Biol Cell 2015;107:111-29.
2. Rimkunas VM, Crosby KE, Li D, Hu Y, Kelly ME, Gu TL, et al. Analysis of receptor tyrosine kinase ROS1-positive tumors in non-small cell lung cancer: identification of a FIG-ROS1 fusion. Clin Cancer Res 2012; 18:4449-57.
3. Takeuchi K, Soda M, Togashi Y, Suzuki R, Sakata S, Hatano S, et al. RET, ROS1 and ALK fusions in lung cancer. Nat Med 2012; 18:378-81.
4. Bergethon K, Shaw AT, Ou SH, Katayama R, Lovly CM, McDonald NT, et al. ROS1 rearrangements define a unique molecular class of lung cancers. J Clin Oncol 2012;30:863-70.
5. Mazieres J, Zalcman G, Crino L, Biondani P, Barlesi F, Filleron T, et al. Crizotinib therapy for advanced lung adenocarcinoma and a ROS1 rearrangement: results from the EUROS1 cohort. J Clin Oncol 2015; 33:992-9.
6. Shaw AT, Ou SH, Bang YJ, Camidge DR, Solomon BJ, Salgia R, et al. Crizotinib in ROS1-rearranged non-small-cell lung cancer. N Engl J Med 2014;371:1963-71.
7. Awad MM, Katayama R, McTigue M, Liu W, Deng YL, Brooun A, et al. Acquired resistance to crizotinib from a mutation in CD74-ROS1. N Engl J Med 2013;368:2395-401.
8. Katayama R, Kobayashi Y, Friboulet L, Lockerman EL, Koike S, Shaw AT, et al. Cabozantinib overcomes crizotinib resistance in ROS1 fusion-positive cancer. Clin Cancer Res 2015;21:166-74.
9. Cheng DT, Mitchell TN, Zehir A, Shah RH, Benayed R, Syed A, et al. Memorial sloan kettering-integrated mutation profiling of actionable cancer targets (MSK-IMPACT): A hybridization capture-based next-generation sequencing clinical assay for solid tumor molecular oncology. J Mol Diagn 2015;17:251-64.
10. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009;45:228-47.
11. Sebaugh JL. Guidelines for accurate EC50/IC50 estimation. Pharm Stat 2011;10:128-34.
12. Epstein LF, Chen H, Emkey R, Whittington DA. The R1275Q neuroblastoma mutant and certain ATP-competitive inhibitors stabilize alternative activation loop conformations of anaplastic lymphoma kinase. J Biol Chem 2012;287:37447-57.
13. Jorgensen WL CJ, Madura JD, Impey RW, Klein ML. Comparison of simple potential functions for simulating liquid water J Chem Phys 1983;79:926.
14. Joung IS, Cheatham TE 3rd. Determination of alkali and halide monovalent ion parameters for use in explicitly solvated biomolecular simulations. J Phys Chem B 2008;112:9020-41.
15. Friesner RA, Murphy RB, Repasky MP, Frye LL, Greenwood JR, Halgren TA, et al. Extra precision glide: docking and scoring incorporating a model of hydrophobic enclosure for protein-ligand complexes. J Med Chem 2006;49:6177-96.
16. Case DA. AMBER 12. University of California, San Fransisco, CA; 2012.
17. Phillips JC, Braun R, Wang W, Gumbart J, Tajkhorshid E, Villa E, et al. Scalable molecular dynamics with NAMD. J Comput Chem 2005;26: 1781-802.
18. Miyamoto S, Kollman PA. Settle: An analytical version of the SHAKE and RATTLE algorithm for rigid water models. J Comput Chem 1992;13:952-62.
19. Darden T, York D, Pedersen L. Particle mesh Ewald: An N⋅log(N) method for Ewald sums in large systems. J Chem Phys 1993;98:10089.
20. Martyna GJ, Tobias DJ, Klein ML. Constant pressure molecular dynamics algorithms. J Chem Phys 1994;101:4177.
21. Pastor RW, Brooks BR, Szabo A. An analysis of the accuracy of Langevin and molecular dynamics algorithms. Mol Phys 1988;65:1409-19.
22. Roe DR, Cheatham TE. PTRAJ and CPPTRAJ: Software for processing and analysis of molecular dynamics trajectory data. J Chem Theory Comput 2013;9:3084-95.
23. Baker NA, Sept D, Joseph S, Holst MJ, McCammon JA. Electrostatics of nanosystems: application to microtubules and the ribosome. Proc Natl Acad Sci U S A 2001;98:10037-41.
24. Warmuth M, Kim S, Gu XJ, Xia G, Adrian F. Ba/F3 cells and their use in kinase drug discovery. Curr Opin Oncol 2007;19:55-60.
25. Zou HY, Li Q, Engstrom LD, West M, Appleman V, Wong KA, et al. PF-06463922 is a potent and selective next-generation ROS1/ALK inhibitor capable of blocking crizotinib-resistant ROS1 mutations. Proc Natl Acad Sci U S A 2015;112:3493-8.
26. Cui JJ, Tran-Dube M, Shen H, Nambu M, Kung PP, Pairish M, et al. Structure based drug design of crizotinib (PF-02341066), a potent and selective dual inhibitor of mesenchymal-epithelial transition factor (c-MET) kinase and anaplastic lymphoma kinase (ALK). J Med Chem 2011;54:6342-63.
27. Song A, Kim TM, Kim DW, Kim S, Keam B, Lee SH, et al. Molecular changes associated with acquired resistance to crizotinib in ROS1-rearranged non-small cell lung cancer (NSCLC). Clin Cancer Res 2015;21:2379-87.
28. Heuckmann JM, Holzel M, Sos ML, Heynck S, Balke-Want H, Koker M, et al. ALK mutations conferring differential resistance to structurally diverse ALK inhibitors. Clin Cancer Res 2011;17: 7394-401.
29. Davare MA, Vellore NA, Wagner JP, Eide CA, Goodman JR, Drilon A, et al. Structural insight into selectivity and resistance profiles of ROS1 tyrosine kinase inhibitors. Proc Natl Acad Sci U S A 2015;112: E5381-90.
30. Ohashi K, Maruvka YE, Michor F, Pao W. Epidermal growth factor receptor tyrosine kinase inhibitor-resistant disease. J Clin Oncol 2013;31:1070-80.
31. Ladanyi M, Pao W. Lung adenocarcinoma: guiding EGFR-targeted therapy and beyond. Mod Pathol 2008;21:S16-22.